Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $717.2 million.

  • Ascendis Pharma A's Cash & Equivalents rose 1994.21% to $717.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $717.2 million, marking a year-over-year increase of 1994.21%. This contributed to the annual value of $696.2 million for FY2025, which is 1643.42% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Cash & Equivalents of $717.2 million as of Q4 2025, which was up 1994.21% from $630.2 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Cash & Equivalents ranged from a high of $848.1 million in Q1 2022 and a low of $278.6 million during Q2 2024
  • In the last 5 years, Ascendis Pharma A's Cash & Equivalents had a median value of $552.0 million in 2025 and averaged $562.7 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Cash & Equivalents plummeted by 4016.82% in 2023, and later skyrocketed by 10074.2% in 2025.
  • Over the past 5 years, Ascendis Pharma A's Cash & Equivalents (Quarter) stood at $510.5 million in 2021, then decreased by 11.12% to $453.8 million in 2022, then fell by 7.01% to $421.9 million in 2023, then soared by 41.71% to $597.9 million in 2024, then grew by 19.94% to $717.2 million in 2025.
  • Its Cash & Equivalents was $717.2 million in Q4 2025, compared to $630.2 million in Q3 2025 and $559.2 million in Q2 2025.